Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets

Pediatric Research

Volumn 66, Issue 4, 2009, Pages 395-399

  Vuckovic, Al ^a   Rondelet, Benoît ^a   Brion, Jean Pierre ^b   Naeije, Robert ^a  

^a Laboratory of Physiology and Physiopathology   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG VASCULAR RESISTANCE; NERVE FIBER; NONHUMAN; PATHOPHYSIOLOGY; PIGLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION;

ANIMALS; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LUNG; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; SIGNAL TRANSDUCTION; SWINE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 70350442810     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3181b33804     Document Type: Article

References (26)

1. Farber HW, Loscalzo J 2004 Pulmonary arterial hypertension. N Engl J Med 351:1655-1665
2. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H 2000 Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269-324
3. Henning RJ, Sawmiller DR 2001 Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 49:27-37
4. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH 2003 Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111:1339-1346
5. Janosi T, Peták F, Fontao F, Morel DR, Beghetti M, Habre W 2008 Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung. Exp Physiol 93:1210-1219
6. Toubas PL, Sekar KC, Sheldon RE, Pahlavan N, Said SI 1988 Vasoactive intestinal peptide prevents increase in pulmonary artery pressure during hypoxia in newborn lambs. Ann N Y Acad Sci 527:686-687
7. Cox CP, Linden J, Said SI 1984 VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 5:325-328
8. Minkes RK, McMahon TJ, Higuera TR, Murphy WA, Coy DH, McNamara DB, Kadowitz PJ 1992 Differential effects of PACAP and VIP on the pulmonary and hindquarters vascular beds of the cat. J Appl Physiol 72:1212-1217
9. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Degene A, Waschek JA, Kort S 2007 Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115:1260-1268
10. Otto C, Hein L, Brede M, Jahns R, Engelhardt S, Grone HJ, Schutz G 2004 Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 110:3245-3251
11. Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, McEntee K, Wauthy P, Salmon I, Ketelslegers JM, Naeije R 2003 Bosentan for the prevention of overcirculation-induced pulmonary hypertension. Circulation 107:1329-1335
12. Winer J, Jung CK, Shackel I, Williams PM 1999 Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41-49
13. Hsu SM 1990 Immunohistochemistry. Methods Enzymol 184:357-363
14. Motulsky HJ 2002 Biostatistique: Une Approche Intuitive. De Boeck Université, Bruxelles, pp 122-124
15. Rondelet B, Kerbaul F, Van Beneden R, Motte S, Fesler P, Hubloue I, Remmelink M, Brimioulle S, Salmon I, Ketelslegers JM, Naeije R 2004 Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 110:2220-2225
16. Rondelet B, Kerbaul F, Vivian GF, Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I, Naeije R 2007 Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension. Pediatr Res 61:284-288
17. Said SI 1988 Vasoactive intestinal peptide in the lung. Ann N Y Acad Sci 527:450-464
18. Busto R, Prieto JC, Bodega G, Zapatero J, Carrero I 2000 Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 21:265-269 (Pubitemid 30182491)
19. Taylor CR, Levenson MR 2006 Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology 49:411-424
20. Asnicar MA, Köster A, Heiman ML, Tinsley F, Smith DP, Galbreath E, Fox N, Ma YL, Blum WF, Hsiung HM 2002 Vasoactive intestinal polypeptide/ pituitary ade-nylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 143:3994-4006
21. Anaid Shahbazian, Petkov V, Baykuscheva-Gentscheva T, Hoeger H, Painsipp E, Holzer P, Mosgoeller W 2007 Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery. Regul Pept 139:102-108
22. Gratton JP, Cournoyer G, Loffler BM, Sirois P, D?Orleans-Juste P 1997 ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension 30:1204-1209
23. de Nucci G, Thomas R, D?Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR 1988 Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85:9797-9800
24. Pitts RL, Wang S, Jones EA, Symes AJ 2001 Transforming growth factor-beta and ciliary neurotrophic factor synergistically induce vasoactive intestinal peptide gene expression through the cooperation of Smad, STAT, and AP-1 sites. J Biol Chem 276:19966-19973
25. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deutsch R, Jamieson SW, Thistlethwaite PA 2003 Signaling molecules in non familial pulmonary hypertension. N Engl J Med 348:500-509 (Pubitemid 36159885)
26. Hamidi SA, Prabhakar S, Said SI 2008 Enhancement of pulmonary vascular remodeling and inflammatory genes with VIP gene deletion. Eur Respir J 31:135-139